Reliability and Validity of Physical Tests and Musculoskeletal Ultrasound As an Add-on in Classifying Anterior Knee Pain
Launched by VRIJE UNIVERSITEIT BRUSSEL · Mar 24, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective physical exams and a special imaging test called musculoskeletal ultrasound (MSU) are in diagnosing a condition known as Anterior Knee Pain Syndrome (AKP). The researchers believe that relying solely on physical exams may not provide enough information to accurately identify the different problems that can cause knee pain in patients aged 7 to 50. By adding MSU, which is a safe and easy way to see what's happening inside the knee, they hope to improve the accuracy of diagnoses.
To participate in the study, individuals must be between 7 and 50 years old and have knee pain that is not caused by an injury. Participants will be asked to understand the study details fully before agreeing to join. During the trial, participants will undergo a physical examination and the MSU test, all within about an hour, without any treatment being given. It’s important for potential participants to note that those with certain knee issues, previous surgeries, or specific health conditions may not be eligible for the study.
Gender
ALL
Eligibility criteria
- • Eligibility criteria are subjects, aged 7 to 50 years, with clinically confirmed non-traumatic anterior knee pain (AKP). Subjects must be able to read, understand, and speak Dutch. Before participation, the study protocol was expressed verbally and in writing, and subsequently informed consent was obtained. In addition, we assessed whether participants did understand it.
- Inclusion Criteria:
- • All consecutive patients presenting clinical symptoms of AKP were screened for eligibility.
- Exclusion Criteria:
- • patients with knee effusion, patients having patella instability, surgeries or previous fractured knee joint in the past, systemic pathology including inflammatory joint disease, and patients with interventions in the last three months including corticosteroid injection or physiotherapy.
About Vrije Universiteit Brussel
The Vrije Universiteit Brussel (VUB) is a distinguished research university located in Brussels, Belgium, known for its commitment to innovative education and cutting-edge research across various disciplines. As a clinical trial sponsor, VUB actively engages in advancing medical knowledge and improving patient care through rigorous scientific investigations. The university fosters collaborations with healthcare institutions and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. VUB's research initiatives are driven by a multidisciplinary approach, leveraging expertise from fields such as medicine, health sciences, and biomedical engineering to address pressing health challenges and contribute to the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Joannes M Hallegraeff, MSc, PhD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported